Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy

Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Sep 20, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for prostate cancer that combines two types of radiation therapy: Focal High Dose Rate (HDR) Brachytherapy Boost and Stereotactic Radiotherapy (sRT). The goal is to find out if this combined treatment can lead to fewer urinary issues compared to standard care. Researchers want to see if patients experience less discomfort and fewer problems with urination after receiving this new treatment.

To be eligible for the trial, participants must have a confirmed diagnosis of prostate cancer and be planning to undergo a specific type of radiation therapy. They should also have a good performance status, meaning they can carry out normal activities with little to no difficulty. There are no specific exclusions for other health issues, making it accessible to many men with prostate cancer. If you join the trial, you will receive treatment and be monitored for any changes in urinary health. This study is currently looking for participants, so if you or someone you know fits the criteria, it could be an opportunity to help advance prostate cancer treatment.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
• • ECOG 0-1
• • Charlson Comorbidity Index ≤ 4
• • Imaging visible disease encompassing \< 50% of the prostate gland and consistent with biopsy findings.
• • Exclusion - none